asa glp 1 recommendations The 2023 position on GLP-1 receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on Here's what your anesthesia team
Description
In a multicenter, randomized, double-blind, placebo-controlled phase 2 trial by NET-PD researchers, pioglitazone was evaluated for its effects on PD progression
The hater called the reality stars skinny figure disturbing in a comment on Tuesday (via Us Weekly)
World Obesity strongly supports WHOs message that pharmacological therapy should be implemented only as part of a comprehensive chronic care model that recognises obesity as a complex, lifelong disease
Metformin and the gastrointestinal tract
